project id: TCGA-PRAD; case submitter id: TCGA-ZG-A9L4; source center: 23; state: released; a260 a280 ratio: 1.8; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.72; rna integrity number: 8.5; age at index: 61; days to birth: -22388; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1950; age at diagnosis: 22388; ajcc clinical m: M0; ajcc clinical t: T1c; ajcc pathologic n: N0; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 1108.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 5; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2011; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 986; initial weight: 170.0; sample id: e2d50dab-ce0f-460a-bdaf-53afc3a50f69; sample submitter id: TCGA-ZG-A9L4-01A; portion id: d74c4b33-22d5-4aa5-8751-7d5192b9c0c8; portion submitter id: TCGA-ZG-A9L4-01A-11; slide id: 2b1a31ba-ce0d-454e-90f4-3411a490c0f7; slide submitter id: TCGA-ZG-A9L4-01A-01-TSA; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 50.0; percent tumor cells: 50.0; percent tumor nuclei: 60.0; section location: TOP;